ClinicalTrials.gg
RecruitingNCT07100873Updated Dec 8, 2025

A Phase 1 Study of ADI-001 in Rheumatoid Arthritis

A Phase 1 interventional study of ADI-001 and Fludarabine in Rheumatoid Arthritis (RA), sponsored by Adicet Therapeutics. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Adicet Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.

Planned enrollment
183rd of 217
25 · median 134
Started
2025
with 34 others
Phase 1
54 of 249
20 open now
Primary completion
2027-03
later than 37 of 71 live
Registered
214th of 249
by date

Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 183rd largest by planned enrollment of the 217 interventional ones that give a count, is one of 35 that started in 2025, is one of 54 in phase 1, reaches primary completion later than 37 of the 71 other live ones, and was the 214th registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:

57 more — sign in →

All 63 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Arthritis, Rheumatoid with a site in China, or all of them as a file.
02

Study summary

ADI-001-106 is a phase 1 study of ADI-001 with a randomized, single-blind, parallel group design to compare two different LD regimens in subjects with treatment-refractory RA. The study will consist of different periods including screening, LD, treatment, and follow-up

03

Conditions studied

  • Rheumatoid Arthritis (RA)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age.
  2. Fulfills the 2010 ACR-EULAR RA classification criteria
  3. Agreement not to take traditional medicines and medications not prescribed by a doctor
  4. Adequate hematological, liver, cardiac and pulmonary function

Exclusion criteria

Exclusion Criteria:

  1. Presence of severe liver disease, class B or C.
  2. disease requiring prednisone higher than 0.5 mg/kg/day (or equivalent).
  3. Subjects unwilling to participate in an extended safety monitoring period (LTFU protocol)
  4. History of a infection (including sepsis, pneumonia, bacteremia, fungal, viral and opportunistic infections) within 4 weeks prior to first dose of study drug which in the opinion of the Investigator may compromise the safety of the subject in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Experimental: Run-in

    Drug: ADI-001 · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Experimental: Part 1a

    Cy/Flu LD

    Drug: ADI-001 · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Experimental: Part 1b

    Cy-only LD

    Drug: ADI-001 · Drug: Cyclophosphamide

  • Experimental
    Experimental: Part 2a

    Cy/Flu LD

    Drug: ADI-001 · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Experimental: Part 2b

    Cy-only LD

    Drug: ADI-001 · Drug: Cyclophosphamide

Interventions

06

What researchers measure

Primary outcomes

  1. The Incidence of Subjects with Dose Limiting Toxicities within each dose level cohort

    This primary endpoint will be used to evaluate safety and tolerability of AD1-001 in subjects with treatment-refractory RA

    Time frame: 28 days

07

Study locations

1 of 1 sites recruiting
  • Adicet Clinical Trials
    Shanghai, Shanghai Municipality, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 17 months after the start.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 17 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Aug 3, 2025
StartActual
Oct 10, 2025
Primary completionEst.
Mar 30, 2027
CompletionEst.
Mar 30, 2028
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07100873
Lead sponsor
Adicet Therapeutics
Responsible party
Sponsor
First posted
Aug 3, 2025
Start date
Oct 10, 2025
Primary completion
Mar 30, 2027 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Dec 8, 2025

Study contacts

Adicet Medical Monitor
Contact
lma@shanghaiadicet.cn
021-61673760

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion